申请人:Schering Corporation
公开号:US05124337A1
公开(公告)日:1992-06-23
N-acyltetrahydroisoquinolines including novel compounds of the formula ##STR1## wherein R.sup.1 is a C10-C25 alkyl chain; a substituted C10-C25 alkyl chain; an interrupted C10-C25 alkyl chain; a substituted interrupted C10-C25 alkyl chain; diphenylamino; di-(R.sup.2 -substituted phenyl)amino; di-(heteroaryl)amino; di-R.sup.2 -substituted heteroary)amino; diphenylmethyl; or di-(R.sup.2 -substituted phenyl)methyl; R.sup.2 is hydroxy, lower alkyl, lower alkoxy, halogeno, amino, lower alkylamino or di-(lower alkyl)amino; R.sup.3, R.sup.4 and R.sup.5 are independently H or --(CH.sub.2 .sub.n --Ar; Ar is phenyl, R.sup.2 -substituted phenyl, heteroaryl or R.sup.2 -substituted heteroaryl; n=0,1 or 2; m=0,1 or 2; or a pharmaceutically acceptable salt thereof, useful in the treatment of atherosclerosis are disclosed.
N-酰基四氢异喹啉包括以下化合物的新型化合物,其化学式为##STR1##其中R.sup.1是C10-C25烷基链;一个取代的C10-C25烷基链;一个中断的C10-C25烷基链;一个取代的中断的C10-C25烷基链;二苯胺基;二-(R.sup.2-取代苯基)胺基;二-(杂环基)胺基;二-R.sup.2-取代的杂环基)胺基;二苯甲基;或二-(R.sup.2-取代苯基)甲基;R.sup.2是羟基,低烷基,低烷氧基,卤素,氨基,低烷基氨基或二-(低烷基)氨基;R.sup.3,R.sup.4和R.sup.5独立地是H或--(CH.sub.2 .sub.n --Ar;Ar是苯基,R.sup.2-取代苯基,杂环基或R.sup.2-取代杂环基;n=0,1或2;m=0,1或2;或其药学上可接受的盐,用于治疗动脉粥样硬化。